ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

Подробнее о видео

Watch the on Radcliffe Cardiology:

In this late-breaking interview from ACC 2022, Dr Frederik Zimmermann (Catharina Hospital, Eindhoven, NL) outlines the main findings of the FAME 3 Trial. FAME 3 is an international, randomised multicentre trial, that aims to compare the outcomes of fractional flow reserve (FFR)-guided PCI and Coronary Artery Bypass Graft Surgery (CABG) in patients with multivessel coronary artery disease. The results suggest that CABG produces better outcomes for three-vessel CAD patients when compared to FFR-guided PCI (NCT02100722).

Discussion Points:
-Study Rationale
-Study Design and Patient Cohort
-Key Findings
-Take-home Messages for Clinicians
-Further Study Required

Recorded on-site in Washington DC, ACC Conference 2022.

Interviewer: Mirjam Boros
Editor: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.